Rituximab treatment for dermatitis herpetiformis in the setting of type 1 diabetes mellitus, celiac disease, vitiligo, autoimmune hemolytic anemia, and autoimmune thrombocytopenia

Affiliations

¹ School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin.
² Department of Medicine, Division of Dermatology, University of Washington, Seattle, Washington.

Case Reports

Katarina T Nguyen et al. JAAD Case Rep. 2020.

. 2020 Jan 22;6(2):122-123.

doi: 10.1016/j.jdcr.2019.12.007. eCollection 2020 Feb.

¹ School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin.
² Department of Medicine, Division of Dermatology, University of Washington, Seattle, Washington.

No abstract available

Keywords: AIHA, autoimmune hemolytic anemia; autoimmune hemolytic anemia; dermatitis herpetiformis; rituximab.

References

1. Nikiphorou E., Hall F.C. First report of improvement of coeliac disease in a patient with Sjögren's syndrome treated with rituximab. Rheumatology (Oxford) 2014;53(10):1906–1907. - PubMed
1. Palazzo C., Nicaise-Roland P., Palazzo E. Rituximab: an effective treatment for rheumatologic and digestive symptoms of celiac disease? Joint Bone Spine. 2012;79(4):422–423. - PubMed
1. Go R.S., Winters J.L., Kay N.E. How I treat autoimmune hemolytic anemia. Blood. 2017;129(22):2971–2979. - PubMed
1. Albers L.N., Zone J.J., Stoff B.K., Feldman R.J. Rituximab treatment for recalcitrant dermatitis herpetiformis. JAMA Dermatol. 2017;153(3):315–318. - PubMed
1. Conconi A., Martinelli G., Thiéblemont C. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003;102(8):2741–2745. - PubMed